Search PubMed⌕ Search

Biomedical subjects

R Kretzschmar

Publications and source records attributed to R Kretzschmar.

At least 19 recordsLinked to original sources
PubMed1997

Absolute Aggregation Rate Constants of Hematite Particles in Aqueous Suspensions: A Comparison of Two Different Surface Morphologies.

Measurements of absolute aggregation rate constants were performed for two samples of well-characterized spheroidal hematite particles with rather different surface morphology. At high ionic strength, the system is in the fast aggregation regime with pH independent rate constants around (1-4) x 10(-18) m3/s. At low ionic strengths, the rate constant is a function of pH and goes through a flat maximum around the point of zero charge (PZC) where fast aggregation conditions are reached. With increasing pH the rate constants increase gradually below the PZC while they decrease very rapidly above the PZC. Above the PZC the rate constants are rather well predicted by the classical DLVO theory. Below the PZC, however, it is necessary to assume a distribution in the surface potentials with a coefficient of variation around 30% to account for the observed behavior. In spite of the pronounced differences in the surface roughness of both hematite samples, their aggregation rate constants are rather similar. Copyright 1997 Academic Press.

Journal Article↗
PubMed1994

Developmental changes of enzymes involved in peptide degradation in isolated rat brain microvessels.

The specific activities of aminopeptidase A (APA), aminopeptidase M (APM), and dipeptidyl-aminopeptidase IV (DP IV) were determined in isolated brain microvessels and in brain homogenate of rats with different ages (between 1 and 8 weeks old). In addition, the blood-brain barrier (BBB)-specific enzymes gamma-glutamyltranspeptidase (gamma-GT) and alkaline phosphatase (ALP) were measured. As similarly described by others, gamma-GT activity increased during this time period by fourfold, whereas ALP increased between weeks 1 and 2 and declined thereafter. DP IV activity increased fivefold during the first 8 weeks after birth and APM activity increased by twofold. A decrease of APA activity was found between weeks 1 and 2 after birth followed by an increase thereafter. The development of aminopeptidase activities responsible for the processing of specific neuropeptides acting on brain microvessels may be important in the development of regulation processes for cerebral blood flow and BBB permeability in the maturing animal.

Aminopeptidases↗
PubMed1992

Age-related pathophysiology of the blood-brain barrier in heat stress.

The possibility that the blood-brain barrier (BBB) might play an important role in the pathophysiology of heat stress (HS) has been examined in young (age 8-9 weeks) and adult (age 24-32 weeks) rats. Exposure of young rats to 4 h HS at 38 degrees C in a biological oxygen demand (BOD) incubator (relative humidity 47-50%, wind velocity 20-26 cm/sec, simulating the environmental conditions of Varanasi, India, during the month of June) resulted in a marked hyperthermia (41.7 +/- 0.23 degrees C) and behavioral symptoms. In these animals there was a profound increase in the permeability of the BBB to Evans blue-albumin (EBA) (464%) and to 131I-sodium iodide (515%), accompanied by a marked increase in the brain water content (4%), of the levels of serotonin (5-hydroxytryptamine, 5-HT) in plasma (687%) and in brain (267%) and a pronounced reduction (30%) in cerebral blood flow (CBF). Morphological examination using light- and electron-microscopy revealed profound neuronal changes associated with a marked increase in glial fibrillary acidic protein (GFAP) and in vimentin immunoreactivities, together with a substantial reduction in myelin basic protein (MBP) immunostaining in the brain. These changes were more pronounced in the brain-stem reticular formation, pons and medulla region. On the other hand, exposure of adult animals to the same intensity of HS resulted in mild or no changes in BBB permeability, content of brain water and 5-HT in the plasma and brain, CBF or other cellular changes.(ABSTRACT TRUNCATED AT 250 WORDS)

Aging↗
PubMed1991

On the blood-brain barrier to peptides: specific binding of atrial natriuretic peptide in vivo and in vitro.

Using the intracarotid bolus injection technique, a saturable binding of [125I]atrial natriuretic peptide (ANP) was found in 8 blood-brain barrier (BBB)-protected rat brain regions as well as in the pineal gland, choroid plexus, neurointermediate and anterior lobes of the pituitary, i.e. structures lacking a BBB. The presence of specific ANP binding on the BBB, here shown for the first time by an in vivo approach, was evidenced concomitantly in vitro by incubation of isolated microvessels. A single-class high affinity binding without regional differences was obtained with Kd = 0.23 nM and Bmax = 120 fmol/mg protein. From that a density of 1,400 binding sites per endothelial cell was calculated, thought to be localized predominantly in the luminal membranes. In the in vivo study, the portion of the extracted peptide that, under the conditions used, may have crossed the BBB by passive diffusion amounted to less than 0.4% of the labeled ANP administered. ANP itself did not change the tightness of the BBB to the non-diffusible reference molecule [14C]inulin. In the BBB-free areas, ANP enhanced the inulin space by nearly 50%.

Animals↗
PubMed1989

Arginine-vasopressin binding to isolated hippocampal microvessels of rats with different endogenous concentrations of the neuropeptide.

The binding of [125I]arginine-8-vasopressin (AVP) to hippocampal microvessels isolated from brains of normal Wistar rats, animals after water deprivation and heterozygous as well as homozygous diabetes-insipidus rats (Brattleboro strain) were measured. Data from binding experiments from the microvessels of the different groups of animals in each case revealed a single class of high affinity binding sites. However, the binding parameters between the different groups of rats were different. The affinity constants differs by a factor of 5.1, ranging from KD = 1.18 nmol X L-1 (animals after water deprivation) to KD = 6.05 nmol X L-1 (homozygous Brattleboro rats). The binding capacity, differing by a factor of 3.5, ranged from Bmax = 245 fmol X mg-1 to Bmax = 865 fmol X mg-1.

Animals↗
PubMed1989

Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs.

In stroke-prone spontaneously hypertensive rats, oral long-term treatment with verapamil, propranolol, hydrochlorothiazide, and dihydralazine attenuated the development of hypertension. The various antihypertensive drugs caused comparable reductions in blood pressure but the calcium antagonist and the beta-receptor blocker prolonged the life span more than the diuretic and vasodilator. The relative heart and lung weights at the time of death were slightly diminished in the verapamil and the high-dose propranolol group. It is assumed that calcium antagonism and beta-receptor blockade prolong the life span, not only due to their blood-pressure-lowering mechanism, but also to the additional protective effects.

Animals↗
PubMed1989

[The x-ray picture of cheirolumbar dysostosis].

Constitutional stenosis of the lumbar vertebral canal and brachycheiria (brachymetacarpia/brachyphalangia) together form cheirolumbar dysostosis (no. 2692 of the Birth Defects Encyclopedia, 1987). Typical findings in the basic type and transitional forms are presented.

Adult↗
PubMed1988

Protective effect of the new calcium antagonist anipamil against isoprenaline-induced cardionecrosis in rats.

The new calcium antagonist anipamil (1,7-bis-(3-methoxyphenyl)-3-methylaza-7-cyano-nonadecane) exhibited a pronounced protective effect against isoprenaline-induced myocardial necrosis in rats. Anipamil was administered in single doses of 10 or 20 mg/kg daily for 4 days. 30 mg/kg isoprenaline was given by subcutaneous injection on the 3rd and 4th days of the study. The protective effect of anipamil was assessed by histological investigations, and its effect on the activity of the enzymes succinate dehydrogenase, NADH-NBT reductase, acid phosphatase and glucose-6-phosphate dehydrogenase in experimentally-induced myocardial damage was assessed quantitatively by microphotometry. The protective effect of anipamil against isoprenaline-induced myocardial necrosis was definitely dose-dependent: 10 mg/kg anipamil exhibited a partial protective effect, whilst 20 mg/kg anipamil protected the heart completely.

Acid Phosphatase↗
PubMed1988

[Pippow's syndrome].

For the first time since the initial report of aplasia of vertebral joints and brachydactyly occurring in a sibship, a similar family history of this rare dystostosis is presented. The following triad of symptoms is significant: a) hypoplasia of the laminae and of the articular and transverse processes of the vertebrae in the thoracolumbar region; b) cranial shift of the vertebral junctions; and c) brachydactyly. "Pippow's syndrome" and "Pippow's dysostosis" are suggested as possible names for this condition.

Abnormalities, Multiple↗
PubMed1986

Vasopressin binds to microvessels from rat hippocampus.

Recent evidence suggests that vasopressin may influence the permeability of the endothelium of brain capillaries. We measured the binding of [125I]arginine-8-vasopressin ([125I]AVP) to microvessels isolated from different regions of the rat brain. The study revealed saturable and specific binding of [125I]AVP to microvessels isolated from hippocampus. Scatchard analysis confirmed a single class of high affinity sites with an equilibrium dissociation constant, Kd, of 3.2 nM and an apparent maximal binding capacity of 205 fmol/mg protein. No binding was observed to microvessels from neocortex and striatum.

Animals↗
PubMed1986

[Characterization of vasopressin receptors in cerebral endothelial cells].

In target cells with receptors of the V2 type, vasopressin activates the adenylate cyclase and induces, finally, a clustering of intramembranous particles in the plasma membrane. Both characteristic effects, however, could not be observed at hippocampal capillaries of the rat. The presumed vasopressin receptors at cerebral capillaries that represent the blood-brain barrier are, therefore, probably not of the V2 type.

Animals↗
PubMed1984

On the blood-brain barrier to peptides: [3H]gonadotropin-releasing hormone accumulation by eighteen regions of the rat brain and by anterior pituitary.

After intracarotid injection of [3H]gonadotropin-releasing hormone ([3H]GnRH) the mean accumulation of radioactivity per unit wet weight of 18 investigated brain samples and the anterior pituitary was 0.38 +/- 0.11% g-1 of the injected tracer dose. This indicates a low but measurable brain uptake of the peptide. The brain uptake of [3H]GnRH in blood-brain barrier (BBB)-protected regions is 5% of that of separately investigated [3H]OH. In BBB-free regions the accumulation of radioactivity was more than 25-fold higher than in BBB-protected regions. The accumulation of [3H]GnRH among regions with BBB varies less than among regions with leaky endothelia. The data presented for [3H]GnRH are similar to those for other peptides so far investigated.

Animals↗
PubMed1984

Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.

The new antiarrhythmic drug propafenone and its main human metabolite 5-hydroxypropafenone were investigated for antiarrhythmic, local anaesthetic, Ca++-antagonistic and beta-adrenoceptor blocking effects as well as for their activity on the central nervous system. In isolated organs (guinea-pig atria, rat aortic strips) 5-hydroxypropafenone had a smaller effect on the maximum following frequency, a greater negative inotropic effect, a greater Ca++-antagonistic effect and a very distinctly weaker beta-adrenoceptor blocking effect than propafenone. Consistent with its antiarrhythmic potency in vitro, intra-cutaneous 5-hydroxypropafenone had a smaller local anaesthetic effect in the guinea pig wheal. In contrast to these findings 5-hydroxypropafenone showed a stronger antiarrhythmic potency in vivo (rat and dog), as demonstrated on the aconitine- and infarction arrhythmias. In addition, in His bundle studies 5-hydroxypropafenone caused a more marked prolongation of the conduction time in atria, AV-node and His-Purkinje system. In vivo the beta-adrenoceptor blocking effect of 5-hydroxypropafenone (isoprenaline tachycardia, rat) was smaller than that of propafenone. The difference between the in vitro and in vivo potency of 5-hydroxypropafenone may be explained by differences in pharmacokinetics, e.g. by a smaller distribution volume compared to propafenone. CNS effects were investigated due to local anaesthetic properties of the substances tested. As indicator of CNS activity anticonvulsant effects, detectably beneath convulsion-inducing doses, were determined in rats (max. electroshock seizures). The results show low CNS activity of propafenone which is even lower for the metabolite but which is distinctly higher for lidocaine and - related to the antiarrhythmic potency - for flecainide, too.(ABSTRACT TRUNCATED AT 250 WORDS)

Anesthetics, Local↗
PubMed1983

6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet aggregation inhibiting and hypotensive activities.

This paper reports on the synthesis and pharmacological activity of 6-aryl-4,5-dihydro-3(2H)-pyridazinone derivatives. The compounds exhibit an aggregation inhibiting action on human platelets in vitro and on rat platelets under ex vivo conditions, as well as a hypotensive action on rats. The strongest pharmacological effects were found with dihydropyridazinones, which have a 6-[p-[(chloroalkanoyl)amino]phenyl] substituent, together with a methyl group in the 5-position. The antiaggregation activity of compounds of this type is in vitro up to 16000 times and ex vivo up to 370 times greater than that of acetylsalicylic acid; the hypotensive action is up to 40 times as great as that of the comparative substance dihydralazine.

Animals↗
PubMed1983

[Round atelectasis].

a) For several reasons Sinner's paper calls for critical remarks: His term "Pleuroma" for a neither pleural nor tumorous but intrapulmonary and atelectatic mass lesion lacks any anatomical and histological basis and is misleading at that because it pretends a tumor of the pleura; his statement in the summary that atelectatic pseudotumors of the lung show a tumorcell-like cytoarchitecture is surprising without being further discussed by the author; he encourages risky invasive diagnostical procedures even in cases where the radiological diagnosis of round atelectasis is unmistakable; already known radiologic features of round atelectases are presented by him as hitherto undescribed; his conceptions of the formal development of round atelectases and of their most characteristic features can not be agreed with. b) The different forms of round atelectases and their residuals are presented with tomograms and with diagrams of their formal development from our point of view.

Bronchiectasis↗